CompletedNot Applicable

Neuroprolotherapy With Physical Therapy for Treatment of Patellar Chondromalacia

Mexico50 participantsStarted 2018-11-01

Plain-language summary

Patellar chondromalacia is the degeneration of articular cartilage located on the posterior face of the patella and may suggest the onset of an osteoarthrosis. It predominates in sedentary people who overload the joint, as well as people with insufficiency in the extensor muscles of the knee. It is often seen between 30 and 40 years. Conservative management is the main treatment option and surgical intervention is considered as a last option in a small number of patients. A new treatment option is neuroprolotherapy where the approach is directed at the subcutaneous nerves as the source of pathology, which can lead to neurogenic inflammation and pain.

Who can participate

Age range

25 Years – 70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients treated in the rehabilitation medicine service of the Specialties Hospital National Medical Center of the West. * Men and women with clinical and radiographic diagnosis of chondromalacia patellae with or without gonarthrosis. * Age over 25 years * Patients expressed their signed consent to participate in the study.... Exclusion Criteria: * Patients who have been infiltrated with corticosteroids in the knee during the last year. * Septic arthritis. * Systemic infection or cutaneous infection at the site of infiltration. * Systemic inflammatory disease. * Joint instability (ligament injuries). * Meniscopathies * Intra-articular fracture * Coagulation disorder or treatment with anticoagulants. * Diabetes mellitus poorly controlled (\> 130mg / dL). * Badly controlled systemic arterial hypertension (\> 140 / 90mmHg). * Hemarthrosis * Pregnancy. * Patients with cognitive disorders that prevent the follow-up of indications or carry out the program. * Patients who do not accept to sign informed consent.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

WOMAC Osteoarthritis Index

Timeframe: 6 weeks

Trial details

NCT IDNCT03515720

SponsorInstituto Mexicano del Seguro Social

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2019-09-20

View on ClinicalTrials.gov More Chondromalacia Patellae trials